{"id":"https://openalex.org/W1495599467","doi":null,"title":"The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.","display_name":"The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.","publication_year":2005,"publication_date":"2005-05-01","ids":{"openalex":"https://openalex.org/W1495599467","mag":"1495599467","pmid":"https://pubmed.ncbi.nlm.nih.gov/16187699"},"language":"en","primary_location":{"id":"pmid:16187699","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16187699","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion","raw_type":"Comparative Study"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5045288021","display_name":"Armando Arredondo","orcid":"https://orcid.org/0000-0002-2768-9966","observed_orcids":["https://orcid.org/0000-0002-2768-9966"]},"institutions":[{"id":"https://openalex.org/I4210128723","display_name":"Instituto Nacional de Salud P\u00fablica","ror":"https://ror.org/032y0n460","country_code":"MX","type":"government","lineage":["https://openalex.org/I4210095685","https://openalex.org/I4210128723"]}],"countries":["MX"],"is_corresponding":false,"raw_author_name":"Armando Arredondo","raw_affiliation_strings":["National Institute of Public Health, Cuernavaca, Mexico. aarredon@insp.mx"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Institute of Public Health, Cuernavaca, Mexico. aarredon@insp.mx","institution_ids":["https://openalex.org/I4210128723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086954528","display_name":"Thomas A. Burke","orcid":"https://orcid.org/0000-0001-6335-0559","observed_orcids":["https://orcid.org/0000-0001-6335-0559"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Thomas A Burke","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108220806","display_name":"George W. Carides","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"George W Carides","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038720341","display_name":"Edith Arely Lemus-Carmona","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Edith Lemus","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5058696188","display_name":"Julio Querol","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Julio Querol","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.2238,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":{"value":0.60735773,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"57","issue":"3","first_page":"399","last_page":"405"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10408","display_name":"Chronic Kidney Disease and Diabetes","score":0.8187999725341797,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10408","display_name":"Chronic Kidney Disease and Diabetes","score":0.8187999725341797,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.15610000491142273,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10291","display_name":"Dialysis and Renal Disease Management","score":0.006000000052154064,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/losartan","display_name":"losartan","score":1.0},{"id":"https://openalex.org/keywords/end-stage-renal-disease","display_name":"end-stage renal disease","score":0.9819999933242798},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9769999980926514},{"id":"https://openalex.org/keywords/diabetic-nephropathy","display_name":"diabetic nephropathy","score":1.0},{"id":"https://openalex.org/keywords/angiotensin-receptor-blockers","display_name":"angiotensin receptor blockers","score":0.8560000061988831},{"id":"https://openalex.org/keywords/lifetime-incidence","display_name":"lifetime incidence","score":0.5460000038146973},{"id":"https://openalex.org/keywords/health-care-costs","display_name":"health care costs","score":0.6959999799728394},{"id":"https://openalex.org/keywords/cost-reduction","display_name":"cost reduction","score":0.7900000214576721},{"id":"https://openalex.org/keywords/competing-risk-analysis","display_name":"competing risk analysis","score":0.703000009059906},{"id":"https://openalex.org/keywords/renaal-trial","display_name":"RENAAL trial","score":0.753000020980835}],"concepts":[{"id":"https://openalex.org/C2780288358","wikidata":"https://www.wikidata.org/wiki/Q410074","display_name":"Losartan","level":4,"score":0.9359577894210815},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8424711227416992},{"id":"https://openalex.org/C61511704","wikidata":"https://www.wikidata.org/wiki/Q1671857","display_name":"Incidence (geometry)","level":2,"score":0.46071988344192505},{"id":"https://openalex.org/C3019080777","wikidata":"https://www.wikidata.org/wiki/Q1754768","display_name":"Cost effectiveness","level":2,"score":0.44619494676589966},{"id":"https://openalex.org/C3019040382","wikidata":"https://www.wikidata.org/wiki/Q476921","display_name":"End stage renal disease","level":3,"score":0.42117050290107727},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4165351986885071},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.3374214172363281},{"id":"https://openalex.org/C2908929049","wikidata":"https://www.wikidata.org/wiki/Q65963433","display_name":"Angiotensin II","level":3,"score":0.33338284492492676},{"id":"https://openalex.org/C2778063415","wikidata":"https://www.wikidata.org/wiki/Q391744","display_name":"Hemodialysis","level":2,"score":0.1407751739025116},{"id":"https://openalex.org/C84393581","wikidata":"https://www.wikidata.org/wiki/Q82642","display_name":"Blood pressure","level":2,"score":0.06259793043136597},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.0},{"id":"https://openalex.org/C120665830","wikidata":"https://www.wikidata.org/wiki/Q14620","display_name":"Optics","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000959","descriptor_name":"Antihypertensive Agents","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D000959","descriptor_name":"Antihypertensive Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003362","descriptor_name":"Cost-Benefit Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D003928","descriptor_name":"Diabetic Nephropathies","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":true},{"descriptor_ui":"D003928","descriptor_name":"Diabetic Nephropathies","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D003928","descriptor_name":"Diabetic Nephropathies","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005500","descriptor_name":"Follow-Up Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006779","descriptor_name":"Hospitals, Public","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006973","descriptor_name":"Hypertension","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D006973","descriptor_name":"Hypertension","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D007349","descriptor_name":"Insurance, Health, Reimbursement","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":false},{"descriptor_ui":"D007676","descriptor_name":"Kidney Failure, Chronic","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D007676","descriptor_name":"Kidney Failure, Chronic","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D007676","descriptor_name":"Kidney Failure, Chronic","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D007676","descriptor_name":"Kidney Failure, Chronic","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D008017","descriptor_name":"Life Expectancy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008800","descriptor_name":"Mexico","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012306","descriptor_name":"Risk","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015337","descriptor_name":"Multicenter Studies as Topic","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":false},{"descriptor_ui":"D015994","descriptor_name":"Incidence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016019","descriptor_name":"Survival Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":false},{"descriptor_ui":"D017281","descriptor_name":"Cost of Illness","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017582","descriptor_name":"Renal Replacement Therapy","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D018572","descriptor_name":"Disease-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019808","descriptor_name":"Losartan","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D019808","descriptor_name":"Losartan","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D047228","descriptor_name":"Angiotensin II Type 1 Receptor Blockers","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D047228","descriptor_name":"Angiotensin II Type 1 Receptor Blockers","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"pmid:16187699","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16187699","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion","raw_type":"Comparative Study"},{"id":"mag:1495599467","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16187699","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":11,"referenced_works":["https://openalex.org/W1984775459","https://openalex.org/W1995945562","https://openalex.org/W1996495603","https://openalex.org/W2020267369","https://openalex.org/W2056976690","https://openalex.org/W2058815839","https://openalex.org/W2109533003","https://openalex.org/W2410571347","https://openalex.org/W2568019769","https://openalex.org/W2796537448","https://openalex.org/W2796700885"],"related_works":["https://openalex.org/W1980927769","https://openalex.org/W1982681360","https://openalex.org/W2892290311","https://openalex.org/W2076913016","https://openalex.org/W1996495603","https://openalex.org/W2429623796","https://openalex.org/W2114546591","https://openalex.org/W2163639688","https://openalex.org/W2156372721","https://openalex.org/W2137555826"],"abstract_inverted_index":{"BACKGROUND:":[0],"The":[1,39,92,170],"RENAAL":[2],"(Reduction":[3],"of":[4,25,41,49,58,81,88,104,120,137,167,174,198,208,219,241,265],"Endpoints":[5],"in":[6,68,132,189,192,195,237,251,272,275,286],"Type":[7],"2":[8,34,149,255],"Diabetes":[9],"with":[10,20,32,95,106,111,124,147,159,183,226,233,249,253],"the":[11,23,47,55,86,101,107,118,121,127,134,156,164,217,222,262],"Angiotensin":[12],"II":[13],"Antagonist":[14],"Losartan)":[15],"study":[16,43],"demonstrated":[17],"that":[18,231],"treatment":[19,232],"losartan":[21,50,138,177,220,234,250],"reduced":[22,261],"risk":[24,87,166],"ESRD":[26,59,96,105,125,162,175,190,266],"by":[27,99,154,163],"29%":[28],"among":[29],"hypertensive":[30],"patients":[31,146,178,185,252],"type":[33,148,254],"diabetes":[35,256],"and":[36,60,140,160,204,221,257,279],"diabetic":[37],"nephropathy.":[38],"objective":[40],"this":[42],"was":[44,75,97,115,152,179],"to":[45,52,77,270,283],"project":[46],"effect":[48],"compared":[51,182],"placebo":[53,184],"on":[54],"lifetime":[56,79,108,135,172,273],"incidence":[57,80,103,173,264],"associated":[61,94,110,123,225],"costs":[62,142],"from":[63,126],"a":[64,193,205,238],"third-party":[65],"payer":[66],"perspective":[67],"Mexico.":[69,287],"METHODS:":[70],"A":[71],"competing":[72],"risks":[73],"method":[74],"used":[76],"estimate":[78],"ESRD,":[82,276],"while":[83],"accounting":[84,215],"for":[85,145,176,216],"death":[89],"without":[90,161],"ESRD.":[91,112,168],"cost":[93,109,114,122,136,197,218,224,281],"estimated":[98,116,153],"combining":[100],"cumulative":[102,165],"Total":[113],"as":[117],"sum":[119],"three":[128],"main":[129],"public":[130,284],"institutions":[131,285],"Mexico,":[133],"therapy,":[139],"other":[141],"(non-ESRD/non-losartan)":[143],"expected":[144],"diabetes.":[150],"Survival":[151],"weighting":[155],"life":[157,210],"expectancies":[158],"RESULTS:":[169],"projected":[171,230,269],"lower":[180],"(66%)":[181],"(83%).":[186],"This":[187],"reduction":[188],"resulted":[191],"decrease":[194],"ESRD-related":[196],"M":[199,242],"dollar":[200,243],"49,737":[201],"per":[202,212,245],"patient":[203],"discounted":[206],"gain":[207],"0.697":[209],"years":[211],"patient.":[213,246],"After":[214],"additional":[223],"greater":[227],"survival,":[228,278],"we":[229],"would":[235],"result":[236,271],"net":[239],"savings":[240,282],"24,073":[244],"CONCLUSION:":[247],"Treatment":[248],"nephropathy":[258],"not":[259],"only":[260],"within-trial":[263],"but":[267],"is":[268],"reductions":[274],"increased":[277],"overall":[280]},"counts_by_year":[{"year":2014,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}